The FDA Found One Sentence Repeated Across Thousands of GLP-1 Prescriptions. That Sentence Was the Only Thing Making Them Legal.

Somewhere in a Houston pharmacy’s records, the same sentence keeps appearing. It is the sentence a prescriber is supposed to write once, for one patient, explaining why that patient cannot use the drug already on the shelf. If that sentence is a template, then the legal reason millions of compounded GLP-1 prescriptions exist is a template too.

I will take a side. The FDA’s warning letter to Empower Pharmacy, dated September 18, 2026, is the most consequential document in compounded GLP-1 regulation since the shortages ended. It is aimed at a failure that patients did not create and will be asked to pay for.

Empower Pharmacy – the FDA Found the Paperwork Before It Found the Patients

The letter carries warning letter number 738238. It is addressed by name to Arta Shaun Noorian, founder and chief executive of Empower Clinic Services, LLC, doing business as Empower Pharmacy, at 7601 N. Sam Houston Parkway West in Houston. It was signed by Clint L. Narver, JD, director of the Office of Compounding Quality and Compliance inside the FDA’s Center for Drug Evaluation and Research, and posted to the agency’s warning letter database.

The inspection behind it ran from November 3 through November 14, 2025. The FDA issued its Form 483, the standard list of observations handed to a firm at the close of an inspection, on November 14, 2025. Empower answered three times: December 8, 2025, March 18, 2026, and April 30, 2026.

The FDA did not need a patient to get sick to write this letter. It needed a spreadsheet.

Section 503A – the Exemption That Only Works If the Reason Is Real

Here is the machinery, because the whole letter is built on it and few people on the patient side of this industry have it explained to them.

A state-licensed pharmacy or a licensed physician compounding under Section 503A escapes three federal requirements at once: full current good manufacturing practice, labeling with adequate directions for use, and prior FDA approval before marketing. That last one is the whole ballgame. It is the entire legal basis of the compounded GLP-1 market, and it is not a loophole. It is a conditional exemption, and one of the conditions is that the pharmacy must not compound, regularly or in inordinate amounts, products that are “essentially copies” of a commercially available drug.

There is an escape hatch inside the escape hatch. Under Section 503A(b)(2), a compounded product is not a copy if there is a change, made for an identified individual patient, that produces for that patient a significant difference from the comparable FDA-approved drug, as determined by the prescribing practitioner. A real determination, by a real prescriber, about a real patient.

Strip the clinical judgment out of that sentence and the exemption disappears. That is what the FDA says it found.

The Volume Problem – When Different Stops Meaning Different

The FDA names three products by their full compounding formulas: tirzepatide with niacinamide, 4 mL at 17/2 mg/mL; tirzepatide with niacinamide, 2.5 mL at 8/2 mg/mL; and semaglutide with cyanocobalamin, the B12 form, 1 mL at 5/0.5 mg/mL.

Then comes the sentence that will be quoted for years. “The volume of products you are producing suggests that differences between products you are compounding and the FDA-approved products are pretextual.”

The agency redacted the actual order counts in the published letter under a Freedom of Information exemption, replacing each figure with a “(b)(4)” placeholder. So the FDA asserts that volume proves the point while refusing to show the reader the number that carries the argument. I am not going to pretend that is a neutral thing for a regulator to do.

It did show a pattern in the records, listing three categories of evidence. First, prescriptions with no prescriber determination of significant difference at all. Second, determinations of “significant difference” that “appear to be repeated verbatim across many records, suggesting that they may be pre-generated for selection by the prescriber, rather than written by the prescriber for an identified individual patient.” Third, the sheer quantity compounded.

Then the line that should worry the telehealth industry: the FDA calls out “third-party technology platforms that provide prescribers with pre-selected menu options for choosing a statement of significant difference,” and says those call “the individualized nature of those determinations into question.”

A menu is not a diagnosis.

The Sterile Room – What the FDA Says It Could Not Verify

The second half of the letter is not about paperwork. It is about injectables, and it is the part I would want a patient to read twice.

The FDA says products intended to be sterile were “prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health.” Two specifics follow. The firm failed to perform adequate smoke studies under dynamic conditions to demonstrate unidirectional airflow in the ISO 5 area, so product “may not provide adequate protection against the risk of contamination.” And the media fills, the simulated production runs a sterile facility uses to prove it can make a batch without contaminating it, “were not performed under the most challenging or stressful conditions.”

Five further good-manufacturing-practice citations follow, covering environmental monitoring in aseptic areas, equipment maintenance, contamination-prevention procedures, process controls, and the quality control unit’s failure to exercise its own judgment.

The part that matters more than any single citation is the cleanup. Empower’s corrective actions, in the agency’s telling, either looked adequate, or could not be evaluated because the supporting documentation was absent, or were deficient.

A smoke study referenced as Rev. 005 was executed March 30 through April 3, 2026, and, per the firm’s own response, remained in “controlled post-execution review” with no final formal summary report provided to the FDA. On a January 2026 media fill, the summary certified no contamination in a stated number of vials. The FDA’s review of the underlying records found vial counts that did not match, undefined entries labeled “N/A,” and results transcribed onto a different form revision because the originals were recorded on the wrong form, with no clear audit trail showing who authorized the rewrite. The agency’s conclusion on that point is blunt: the claim that all vials were inspected and none showed contamination “cannot be supported if records do not clearly demonstrate that all vials were accounted for and inspected.”

To be precise about what the letter does not say, because precision is the whole job here: the FDA did not find, and did not allege, that contaminated GLP-1 product reached patients. It found a documentation trail it could not follow. The containment systems worked right up until the moment someone asked to see the paperwork.

Shaun Noorian – “We Have Already Remediated Many of the Issues”

Empower’s chief executive gave the Houston Chronicle a statement: “We have already remediated many of the issues outlined in the Warning Letter, and look forward to working with the FDA to address the remaining matters expeditiously and comprehensively to the agency’s satisfaction.” He noted that the company has been FDA-registered for more than a decade and said Empower views regulatory oversight as “essential to safe compounding.”

The letter gives the firm fifteen working days from receipt to respond in writing, and closes with the standard consequence language: failure to adequately address the violations “may result in legal action without further notice, including, without limitation, seizure and injunction.”

The Chronicle also reports that this is the fifth FDA warning letter the agency has sent Empower since 2017. I could not verify that count against a single authoritative page in this run. The FDA’s public record plainly shows earlier Empower letters in 2017, 2021 and 2025, and I am attributing the “fifth” figure to the Chronicle rather than asserting it myself. If it holds, a decade of repeating findings is not a paperwork problem. It is a business model.

If You Take a Compounded GLP-1 – What This Letter Does and Does Not Do

Start with what it does not do. It does not make compounded GLP-1s illegal. It does not name a clinic, a telehealth platform, or a patient. It applies Section 503A to one firm’s records, and it remains one firm’s regulatory problem until the FDA says otherwise.

Then the part patients need to hold onto. The FDA states plainly, on its own GLP-1 concerns page, that compounded drugs are not FDA-approved and that the agency does not review compounded drugs for safety, effectiveness, or quality before they are marketed. That page also records 605 adverse event reports associated with compounded semaglutide and 545 associated with compounded tirzepatide, as of July 31, 2025, with the agency’s own caveat that reporting from state-licensed pharmacies is not mandatory, so the true number is likely higher.

The timeline behind the “significant difference” question matters too. The letter’s own footnotes confirm that the FDA’s enforcement discretion for state-licensed pharmacies compounding copies of these products ended for tirzepatide on March 5, 2025, and for semaglutide on April 24, 2025. Compounded GLP-1 prescriptions written after those dates rest entirely on the individual determination the FDA now says looked pre-generated.

Several things remain unknown. Whether the FDA pursues seizure or injunction against Empower. Whether warning letters follow to the telehealth platforms the letter names in category rather than by name. Whether the agency’s volume-as-evidence argument survives a court, given that it redacted the numbers used to make that argument. Those are open questions, and anyone telling you this resolves them is selling something.

My advice is narrow. If you are on a compounded GLP-1, the move is not to stop. It is to ask your prescriber one specific question: what change did your prescriber make for you, specifically, and why did it matter for you? If the answer sounds like a line off a dropdown, you have learned something about your own file. That question is free, it is legal, and no dropdown can answer it.

The FDA spent a year on this letter. The finding that should rattle the industry is not a smoke study. It is that the single sentence distinguishing a legal compounded drug from an illegal copy may have been generated for convenience, at scale, by software, and that the patients who trusted the process are the only people in the chain who cannot fix it.

Sources: FDA, Houston Chronicle, FDA (Drug Alerts).

Axel Rodes writes for Find Peptide Clinics. This is reporting, not medical advice. Compounded drug products are not FDA-approved, and nothing here is dosing guidance. Talk to a licensed prescriber about your own treatment.

Which of these compounds may a compounding pharmacy lawfully prepare, and in which state? The peptide regulatory status tracker sets out FDA status compound by compound, with dates and sources.